Specifically, the combination of targeting asparagine and anti-PD-L1 therapy can exert significant anti-tumor effects in vivo, and the efficacy of this combined treatment is dependent on CD8+ T cell infiltration within the tumor immune microenvironment. Here, CD8A is linked to neoplasm.